Argenx Strikes Potential $1.15B Unnatural Products Deal to Expand Oral Peptides

Immunology-focused biotech argenx has agreed to purchase Unnatural Products to gain access to the company’s orally-delivered macrocyclic peptides for intracellular targets that have proven to be difficult or even impossible for conventional drugs to reach.

Unnatural Products has dedicated the past decade to building an integrated discovery platform that uses massively parallel synthesis and direct-to-biology screening along with AI to engineer macrocycles at scale. Today, it is a leading platform company in macrocyclic peptides.

“Our ambition is to be the leading immunology innovation company, and as argenx builds its next chapter, we are investing with discipline where it will count the most for patients,” said Karen Massey, CEO of argenx. “UNP adds macrocyclic peptide capabilities that are highly complementary to our antibody engineering and creates new possibilities for oral and long-acting medicines."

In addition to an upfront payment of $550 million, argenx will make developmental and regulatory milestones, resulting in a total of up to $1.15 billion. The deal is expected to close at the end of the year, upon which Unnatural Products will continue operating at its current site but will become part of argenx’s global research organization.

 

Subscribe to our e-Newsletters
Stay up to date with the latest news, articles, and events. Plus, get special offers from Tablets & Capsules – all delivered right to your inbox! Sign up now!